In a 37‑page memorandum ruling, U.S. District Judge David C. Joseph of the Western District of Louisiana granted the Trump administration’s request to pause the case pending the FDA’s promised “good faith, evidence-based and expeditious review” of Mifepristone’s safety risks. The ruling temporarily denies Louisiana’s effort to roll back the FDA’s 2023 decision to let Mifepristone be dispensed by mail and telehealth without an in‑person medical visit.
The lawsuit, filed in October 2025, argues that the FDA acted unlawfully under the Administrative Procedure Act (APA) by loosening Mifepristone’s safeguards without adequate scientific justification. An April 2025 study from the Ethics and Public Policy Center found that nearly 11 percent of women who take Mifepristone experience serious adverse health events, including “sepsis, infection, hemorrhage, need for blood transfusion, hospitalization, emergency room visits related to the abortion, need for a surgical abortion due to incomplete abortion, and other abortion-specific complications.”
Louisiana contends the FDA failed to consider these cumulative safety effects and relied on missing or compromised data regarding adverse events. Louisiana further argues that the FDA’s actions undermine state abortion laws and impose financial burdens on the state, particularly through Medicaid costs associated with emergency care following chemical abortions.
While declining to issue immediate relief to Louisiana and Markezich, Judge Joseph found they have Article III (federal) standing to bring their claims. The U.S. Supreme Court had previously dismissed another Mifepristone case in 2024 for lack of standing (FDA v. Alliance for Hippocratic Medicine), but this case is different because the FDA’s Mifepristone Risk Evaluation and Mitigation Strategy (REMS), implemented by the Biden administration, undermines Louisiana’s abortion laws, the ruling states.